

Development of SHP2 allosteric inhibitor with dual mechanisms of targeting the RAS pathway and enhancing anti-tumor immunity

KANAPH Therapeutics Inc.



ONCOLOGY	Candidate
Product Type	Chemical - Small Molecule
Indication	NSCLC, Colorectal Cancer, Head and Neck Cancer, Esophageal Cancer
Target	SHP2(Src homology region 2-containing protein tyrosine phosphatase 2)
MoA(Mechanism of Action)	<ol style="list-style-type: none"> 1. SHP2 inhibitor blocks RAS/MAPK signaling and functions as pan-KRAS inhibitor, covering diverse KRAS mutations. 2. SHP2 inhibitor stimulates anti-tumor immunity in the TME.
Competitiveness	<ol style="list-style-type: none"> 1. Kanaph's SHP2 inhibitor shows greater in vitro and in vivo efficacy in comparison to the most advanced SHP2 program (TNO-155, Novartis). 2. It can also target various SHP2 activating mutants, which is not achievable by TNO-155. 3. Kanaph is aiming to develop a SHP2 inhibitor with high BBB penetration, thereby beneficial for the NSCLC and breast cancer patients with brain metastases.
Development Stage	Candidate
Route of Administration	Oral